| Biomarker ID | 1842 |
| PMID | 30890858 |
| Year | 2019 |
| Biomarker | MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1); |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Tumor Stage T1C Vs T2 |
| Type of Biomarker | Prognostic |
| Cohort | 14 patients had tumor stage T1c, 10 had T2, 23 had T2a, 11 had T2b, 30 had T2c, 2 had T3, 6 had T3a, 8 had T3b, 1 had T4. Dataset: Long et. all |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.971 |
| Accuracy | 95.8% |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |